Publications

  1. Karnes RJ, Murphy CR, Bergstralh EJ, DiMonte G, Cheville JC, Lowe VJ, Mynderse LA, Kwon ED. Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Detected by C-Choline Positron Emission Tomography/Computed Tomography. J Urol. 2014 Aug 20.
    View PubMed
  2. Gibbons RM, Liu X, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-H1 signaling is integrated during CD8(+) T cell priming and restrains effector differentiation. Cancer Immunol Immunother. 2014 Aug; 63(8):859-67. Epub 2014 Jun 04.
    View PubMed
  3. Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014 Jul; 9(7):1036-40.
    View PubMed
  4. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry MB, Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Jun; 15(7):700-12. Epub 2014 May 13.
    View PubMed
  5. Tollefson MK, Karnes RJ, Kwon ED, Lohse CM, Rangel LJ, Mynderse LA, Cheville JC, Sebo TJ. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model. Mayo Clin Proc. 2014 Mar; 89(3):308-18. Epub 2014 Jan 31.
    View PubMed
  6. Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Kufer R, Zerbib M, Kwon E, Thompson RH, Boorjian SA, Shariat SF. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol. 2014 Jan; 40(1):121-7. Epub 2013 Sep 18
    View PubMed
  7. Joseph RW, Parasramka M, Eckel-Passow JE, Serie D, Wu K, Jiang L, Kalari K, Thompson RH, Huu Ho T, Castle EP, Cheville J, Kwon ED, Thompson EA, Parker A. Inverse Association between Programmed Death Ligand 1 and Genes in the VEGF Pathway in Primary Clear Cell Renal Cell Carcinoma. Cancer Immunol Res. 2013 Dec; 1(6):378-85. Epub 2013 Aug 29.
    View PubMed
  8. Liu X, Gibbons RM, Harrington SM, Krco CJ, Markovic SN, Kwon ED, Dong H. Endogenous tumor-reactive CD8 T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. Oncoimmunology. 2013 Jun 1; 2(6):e23972. Epub 2013 Jun 06.
    View PubMed
  9. Zhang BY, Thompson RH, Lohse CM, Dronca RS, Cheville JC, Kwon ED, Leibovich BC. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up. BJU Int. 2013 Jun; 111(7):1046-53. Epub 2013 Apr 02.
    View PubMed
  10. Mitchell CR, Lowe VJ, Rangel LJ, Hung JC, Kwon ED, Karnes RJ. Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol. 2013 Apr; 189(4):1308-13. Epub 2012 Oct 30
    View PubMed
  11. Boland JM, Kwon ED, Harrington SM, Wampfler JA, Tang H, Yang P, Aubry MC. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer. 2013 Mar; 14(2):157-63. Epub 2012 Aug 04.
    View PubMed
  12. Junker K, Ficarra V, Kwon ED, Leibovich BC, Thompson RH, Oosterwijk E. Potential role of genetic markers in the management of kidney cancer. Eur Urol. 2013 Feb; 63(2):333-40. Epub 2012 Sep 24.
    View PubMed
  13. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Frontiers in Oncology. 2013; 2 JAN:215.
  14. Gibbons RM, Liu X, Pulko V, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. Oncoimmunology. 2012 Oct 1; 1(7):1061-73.
    View PubMed
  15. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2012; 2:215. Epub 2013 Jan 22.
    View PubMed
  16. Pulko V, Harris KJ, Liu X, Gibbons RM, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-h1 expressed by activated CD8 T cells is essential for their survival. J Immunol. 2011 Dec 1; 187(11):5606-14. Epub 2011 Oct 24.
    View PubMed
  17. Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, Leibovich B, Blute ML, Dong H, Kwon ED. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011 Apr 1; 17(7):1915-23. Epub 2011 Feb 25.
    View PubMed
  18. Parker AS, Heckman MG, Sheinin Y, Wu KJ, Hilton TW, Diehl NN, Pisansky TM, Schild SE, Kwon ED, Buskirk SJ. Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Apr 1; 79(5):1343-9. Epub 2010 Jul 02.
    View PubMed
  19. Wada DA, Wilcox RA, Harrington SM, Kwon ED, Ansell SM, Comfere NI. Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sezary syndrome. Am J Hematol. 2011 Mar; 86(3):325-7. Epub 2011 Feb 15.
    View PubMed
  20. Archibald DJ, Neff BA, Voss SG, Splinter PL, Driscoll CL, Link MJ, Dong H, Kwon ED. B7-H1 expression in vestibular schwannomas. Otol Neurotol. 2010 Aug; 31(6):991-7.
    View PubMed
  21. Eckel-Passow JE, Lohse CM, Sheinin Y, Crispen PL, Krco CJ, Kwon ED. Tissue microarrays: one size does not fit all. Diagn Pathol. 2010; 5:48. Epub 2010 Jul 07.
    View PubMed
  22. Boorjian SA, Sheinin Y, Crispen PL, Lohse CM, Leibovich BC, Kwon ED. T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Urology. 2009 Dec; 74(6):1359-64. Epub 2009 Jun 07.
    View PubMed
  23. Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, Kwon ED, Dong H. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol. 2009 Sep 15; 183(6):3634-41. Epub 2009 Aug 26.
    View PubMed
  24. Wilcox RA, Feldman AL, Wada DA, Yang ZZ, Comfere NI, Dong H, Kwon ED, Novak AJ, Markovic SN, Pittelkow MR, Witzig TE, Ansell SM. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009 Sep 3; 114(10):2149-58. Epub 2009 Jul 13.
    View PubMed
  25. Parker AS, Leibovich BC, Lohse CM, Sheinin Y, Kuntz SM, Eckel-Passow JE, Blute ML, Kwon ED. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer. 2009 May 15; 115(10):2092-103.
    View PubMed
  26. Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, Blute ML, Sebo TJ, Tindall DJ, Kwon ED, Karnes RJ. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res. 2009 Mar 15; 15(6):2174-80. Epub 2009 Mar 10.
    View PubMed
  27. Thompson RH, Kwon ED, Allison JP. Inhibitors of B7-CD28 costimulation in urologic malignancies. Immunotherapy. 2009 Jan; 1(1):129-39.
    View PubMed
  28. Inman BA, Davies JD, Rangel LJ, Bergstralh EJ, Kwon ED, Blute ML, Karnes RJ, Leibovich BC. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. Cancer. 2008 Oct 1; 113(7):1544-51.
    View PubMed
  29. Boorjian SA, Sheinin Y, Crispen PL, Lohse CM, Kwon ED, Leibovich BC. Hormone receptor expression in renal angiomyolipoma: clinicopathologic correlation. Urology. 2008 Oct; 72(4):927-32. Epub 2008 Mar 28.
    View PubMed
  30. Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, Kwon ED. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Urol. 2008 Oct; 180(4 Part 1):1302.
    View PubMed
  31. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008 Aug 15; 14(16):5150-7. Epub 2008 Aug 11.
    View PubMed
  32. Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Cheville JC, Blute ML, Russo P, Kwon ED, Allison JP. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res. 2008 Aug 1; 68(15):6054-8.
    View PubMed
  33. Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer. 2008 Aug 1; 113(3):450-60.
    View PubMed
  34. Boorjian SA, Sheinin Y, Crispen PL, Farmer SA, Lohse CM, Kuntz SM, Leibovich BC, Kwon ED, Frank I. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008 Aug 1; 14(15):4800-8.
    View PubMed
  35. Parker AS, Lohse CM, Leibovich BC, Cheville JC, Sheinin YM, Kwon ED. Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma. Hum Pathol. 2008 Aug; 39(8):1176-84. Epub 2008 Jun 05.
    View PubMed
  36. Jiang Z, Lohse CM, Chu PG, Wu CL, Woda BA, Rock KL, Kwon ED. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer. 2008 Jun 15; 112(12):2676-82.
    View PubMed
  37. Yossepowitch O, Thompson RH, Leibovich BC, Eggener SE, Pettus JA, Kwon ED, Herr HW, Blute ML, Russo P. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol. 2008 Jun; 179(6):2158-63.
    View PubMed
  38. Routh JC, Ashley RA, Sebo TJ, Lohse CM, Husmann DA, Kramer SA, Kwon ED. B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. J Urol. 2008 May; 179(5):1954-9; discussion 1959-60. Epub 2008 Mar 20.
    View PubMed
  39. Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z, Kwon ED. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 2008 Apr 1; 112(7):1471-9.
    View PubMed
  40. Inman BA, Frigola X, Harris KJ, Kuntz SM, Lohse CM, Leibovich BC, Kwon ED. Questionable relevance of gamma delta T lymphocytes in renal cell carcinoma. J Immunol. 2008 Mar 1; 180(5):3578-84.
    View PubMed
  41. Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC, Blute ML. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol. 2008 Feb; 179(2):468-71; discussion 472-3.
    View PubMed
  42. Magera JS Jr, Leibovich BC, Lohse CM, Sengupta S, Cheville JC, Kwon ED, Blute ML. Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology. 2008 Feb; 71(2):278-82.
    View PubMed
  43. Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, Kwon ED. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol. 2007 Oct 20; 25(30):4757-64.
    View PubMed
  44. Tollefson MK, Thompson RH, Sheinin Y, Lohse CM, Cheville JC, Leibovich BC, Kwon ED. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer. 2007 Aug 15; 110(4):783-90.
    View PubMed
  45. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, Cheville JC, Sebo TJ, Kwon ED. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007 Aug 15; 67(16):7893-900. Epub 2007 Aug 08.
    View PubMed
  46. Thompson RH, Blute ML, Krambeck AE, Lohse CM, Magera JS, Leibovich BC, Kwon ED, Frank I, Cheville JC. Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion. Am J Surg Pathol. 2007 Jul; 31(7):1089-93.
    View PubMed
  47. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007 Apr 15; 109(8):1499-505.
    View PubMed
  48. Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, Kwon ED. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007 Apr 1; 13(7):2075-81.
    View PubMed
  49. Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, Blute ML, Sebo TJ, Cheville JC, Parker AS, Kwon ED. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res. 2007 Mar 15; 13(6):1749-56.
    View PubMed
  50. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007 Mar 15; 13(6):1757-61.
    View PubMed
  51. Inman BA, Frigola X, Dong H, Kwon ED. Costimulation, coinhibition and cancer. Curr Cancer Drug Targets. 2007 Feb; 7(1):15-30.
    View PubMed
  52. Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG Jr, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):667s-670s.
    View PubMed
  53. Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):709s-715s.
    View PubMed
  54. Mercader M, Sengupta S, Bodner BK, Manecke RG, Cosar EF, Moser MT, Ballman KV, Wojcik EM, Kwon ED. Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int. 2007 Jan; 99(1):60-7.
    View PubMed
  55. Thompson RH, Kwon ED. Significance of B7-H1 overexpression in kidney cancer. Clin Genitourin Cancer. 2006 Dec; 5(3):206-11.
    View PubMed
  56. Dimashkieh HH, Lohse CM, Blute ML, Kwon ED, Leibovich BC, Cheville JC. Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma. J Urol. 2006 Nov; 176(5):1978-82; discussion 1982-3.
    View PubMed
  57. Krambeck AE, Leibovich BC, Lohse CM, Kwon ED, Zincke H, Blute ML. The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J Urol. 2006 Nov; 176(5):1990-5.
    View PubMed
  58. Blocki FA, Radhakrishnan S, Van Keulen VP, Heckman KL, Ciric B, Howe CL, Rodriguez M, Kwon E, Pease LR. Induction of a gene expression program in dendritic cells with a cross-linking IgM antibody to the co-stimulatory molecule B7-DC. FASEB J. 2006 Nov; 20(13):E1780-9.
    View PubMed
  59. Thompson RH, Allison JP, Kwon ED. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol. 2006 Sep-Oct; 24(5):442-7.
    View PubMed
  60. Inman BA, DiMarco DS, Slezak JM, Sebo TJ, Kwon ED, Leibovich BC, Blute ML, Zincke H. Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy. Urology. 2006 Sep; 68(3):604-8. Epub 2006 Sep 18.
    View PubMed
  61. Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Zincke H, Blute ML. Second primary malignancies associated with renal cell carcinoma histological subtypes. J Urol. 2006 Sep; 176(3):900-3; discussion 903-4.
    View PubMed
  62. Ashley RA, Inman BA, Sebo TJ, Leibovich BC, Blute ML, Kwon ED, Zincke H. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer. 2006 Aug 15; 107(4):712-20.
    View PubMed
  63. Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006 Jul 5; 103(27):10391-6. Epub 2006 Jun 23.
    View PubMed
  64. Webster WS, Lohse CM, Thompson RH, Dong H, Frigola X, Dicks DL, Sengupta S, Frank I, Leibovich BC, Blute ML, Cheville JC, Kwon ED. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer. 2006 Jul 1; 107(1):46-53.
    View PubMed
  65. Parker AS, Kosari F, Lohse CM, Houston Thompson R, Kwon ED, Murphy L, Riehle DL, Blute ML, Leibovich BC, Vasmatzis G, Cheville JC. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer. 2006 Jul 1; 107(1):37-45.
    View PubMed
  66. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006 Apr 1; 66(7):3381-5.
    View PubMed
  67. Sengupta S, Lohse CM, Cheville JC, Leibovich BC, Thompson RH, Webster WS, Frank I, Zincke H, Blute ML, Kwon ED. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer. 2006 Jan 15; 106(2):304-12.
    View PubMed
  68. Sengupta S, Cheville JC, Corless CL, Lohse CM, Heinrich MC, Kwon ED, Zincke H, Blute ML, Leibovich BC. Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma. J Urol. 2006 Jan; 175(1):53-6.
    View PubMed
  69. Karnes RJ, Whelan CM, Kwon ED. Immunotherapy for prostate cancer. Curr Pharm Des. 2006; 12(7):807-17.
    View PubMed
  70. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer. 2005 Nov 15; 104(10):2084-91.
    View PubMed
  71. Webster WS, Small EJ, Rini BI, Kwon ED. Prostate cancer immunology: Biology, therapeutics, and challenges. J Clin Oncol. 2005 Nov 10; 23(32):8262-9.
    View PubMed
  72. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. J Urol. 2005 Nov; 174(5):1759-63.
    View PubMed
  73. Thompson RH, Webster WS, Cheville JC, Lohse CM, Dong H, Leibovich BC, Kuntz SM, Sengupta S, Kwon ED, Blute ML. B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology. 2005 Nov; 66(5 Suppl):10-4.
    View PubMed
  74. Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Frank I, Zincke H, Blute ML. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol 2005 Oct; 174(4 Pt 1):1218-21.
    View PubMed
  75. Sengupta S, Lohse CM, Leibovich BC, Frank I, Thompson RH, Webster WS, Zincke H, Blute ML, Cheville JC, Kwon ED. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005 Aug 1; 104(3):511-20.
    View PubMed
  76. Thompson RH, Cheville JC, Lohse CM, Webster WS, Zincke H, Kwon ED, Frank I, Blute ML, Leibovich BC. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer. 2005 Jul 1; 104(1):53-60.
    View PubMed
  77. Gillett MD, Cheville JC, Karnes RJ, Lohse CM, Kwon ED, Leibovich BC, Zincke H, Blute ML. Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol. 2005 Jun; 173(6):1893-6.
    View PubMed
  78. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Kwon ED, Frank I, Thompson RH, Blute ML. Cancer specific survival for patients with pT3 renal cell carcinoma - Can the 2002 primary tumor classification be improved? J Urol. 2005 Mar; 173(3):716-9.
    View PubMed
  79. Thompson RH, Leibovich BC, Cheville JC, Lohse CM, Frank I, Kwon ED, Zincke H, Blute ML. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a? J Urol. 2005 Mar; 173(3):918-21.
    View PubMed
  80. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Kwon ED, Zincke H. pT2 classification for renal cell carcinoma. Can its accuracy be improved? J Urol. 2005 Feb; 173(2):380-4.
    View PubMed
  81. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED. Aberrant expression of costimulatory B7-H1 in clear cell renal cell carcinoma. The American Journal of Urology Review. 2005; 3(5):244-9.
    View PubMed
  82. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004 Dec 7; 101(49):17174-9. Epub 2004 Nov 29.
    View PubMed
  83. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004 Nov 15; 173(10):6098-108.
    View PubMed
  84. Mulhall JP, Martin DJ, Lubrano T, Moser M, Kwon E, Wojcik E, Shankey TV. Peyronie's disease fibroblasts demonstrate tumorigenicity in the severe combined immunodeficient (SCID) mouse model. Int J Impot Res. 2004 Apr; 16(2):99-104.
    View PubMed
  85. Krejci KG, Markiewicz MA, Kwon ED. Immunotherapy for urological malignancies. J Urol. 2004 Feb; 171(2 Part 1):870-6.
    View PubMed
  86. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma - A stratification tool for prospective clinical trials. Cancer. 2003 Apr 1; 97(7):1663-71.
    View PubMed
  87. Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED. Prostate cancer - Advances in immunotherapy. Biodrugs. 2003; 17(2):131-8.
    View PubMed
  88. Shah AH, Tabayoyong WB, Kundu SD, Kim SJ, Van Parijs L, Liu VC, Kwon E, Greenberg NM, Lee C. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res. 2002 Dec 15; 62(24):7135-8.
    View PubMed
  89. Moore DK, Kwon EE, Donovan JF. Continent jejunal reservoir dialysis for end-stage renal disease: is it possible? J Endourol. 2002 Oct; 16(8):575-80.
    View PubMed
  90. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A. 2001 Dec 4; 98(25):14565-70.
    View PubMed
  91. Yang D, Holt GE, Velders MP, Kwon ED, Kast WM. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res. 2001 Aug 1; 61(15):5857-60.
    View PubMed
  92. Ellis TM, Moser MT, Le PT, Flanigan RC, Kwon ED. Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice. Int Immunol. 2001 Apr; 13(4):553-8.
    View PubMed
  93. Hurwitz AA, Kwon ED, van Elsas A. Costimulatory wars: the tumor menace. Curr Opin Immunol. 2000 Oct; 12(5):589-96.
    View PubMed
  94. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000 May 1; 60(9):2444-8.
    View PubMed
  95. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000 May; 6(5):1755-66.
    View PubMed
  96. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A. 1999 Dec 21; 96(26):15074-9.
    View PubMed
  97. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 1997 Aug 15; 57(16):3325-30.
    View PubMed
  98. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A. 1997 Jul 22; 94(15):8099-103.
    View PubMed
  99. Burg MB, Kwon ED, Kultz D. Regulation of gene expression by hypertonicity. Annu Rev Physiol. 1997; 59:437-55.
    View PubMed
  100. Burg MB, Kwon ED, Peters EM. Glycerophosphocholine and betaine counteract the effect of urea on pyruvate kinase. Kidney Int Suppl. 1996 Dec; 57:S100-4.
    View PubMed
  101. Burg MB, Kwon ED, Kultz D. Osmotic regulation of gene expression. FASEB J. 1996 Dec; 10(14):1598-606.
    View PubMed
  102. Cooper CS, Kwon ED, Donovan JF Jr. Traumatic ureteroduodenal fistula. Journal of Trauma-Injury Infection & Critical Care. 1996 Sep; 41(3):553-5.
    View PubMed
  103. Kwon ED, Dooley JA, Jung KY, Andrews PM, Garcia-Perez A, Burg MB. Organic osmolyte distribution and levels in the mammalian urinary bladder in diuresis and antidiuresis. Am J Physiol. 1996 Jul; 271(1 Pt 2):F230-3.
    View PubMed
  104. Kwon ED, Donovan JF, Schedl HP. Physical determinants of solute and water clearance by the perfused dog jejunum. J Surg Res. 1996 Feb 15; 61(1):215-20.
    View PubMed
  105. Kwon ED, Zablocki K, Peters EM, Jung KY, Garcia-Perez A, Burg MB. Betaine and inositol reduce MDCK cell glycerophosphocholine by stimulating its degradation. Am J Physiol. 1996 Jan; 270(1 Pt 1):C200-7.
    View PubMed
  106. Donovan JF Jr, Hade DK, Lavelle JP, Kwon ED. Continent small-intestine reservoir construction: a tapered intussusceptum promotes sustained continence. World J Urol. 1996; 14(6):370-4.
    View PubMed
  107. Kwon ED, Zablocki K, Jung KY, Peters EM, Garcia-Perez A, Burg MB. Osmoregulation of GPC:choline phosphodiesterase in MDCK cells: different effects of urea and NaCl. Am J Physiol. 1995 Jul; 269(1 Pt 1):C35-41.
    View PubMed
  108. Kwon ED, Jung KY, Edsall LC, Kim HY, Garcia-Perez A, Burg MB. Osmotic regulation of synthesis of glycerophosphocholine from phosphatidylcholine in MDCK cells. Am J Physiol. 1995 Feb; 268(2 Pt 1):C402-12.
    View PubMed
  109. Kwon ED, Schedl HP, Donovan JF Jr. Deoxycholate effects on plasma solute clearance by gut perfusion in dog. J Surg Res. 1994 Nov; 57(5):549-55.
    View PubMed
  110. Hade DK, Donovan JF Jr, Kwon ED, Stokes JB, Bertholf MB, Flanigan MJ, Schedl HP. The use of rhein to augment fluid and electrolyte secretion in the continent jejunal reservoir. Surg Forum. 1994; XLV:791-4.
  111. Kwon ED, Schedl HP, Donovan JF, Carson RA, Williams RD. Transport properties of an in situ jejunal reservoir in dogs. Am J Physiol. 1992 Mar; 262(3 Pt 2):F517-22.
    View PubMed
  112. Kwon ED, Loening SA, Hawtrey CE. Radical prostatectomy and adjuvant radioactive gold seed placement: results of treatment at 5 and 10 years for clinical stages A2, B1 and B2 cancer of the prostate. J Urol. 1991 Mar; 145(3):524-31.
    View PubMed
  113. Kwon ED, Donovan JF, Schedl HP, Williams RD. Replacement of lost renal function: Solute and coupled urea nitrogen and hydrogen ion excretion in the jejunal reservoir/urease system. Surgical Form. 1991;XLII.
  114. Kwon ED, Williams RD. Magnetic resonance imaging in the evaluation of prostate cancer. World J Urol. 1989; 7:17-21.
  115. Loening SA, Kwon ED. Percutaneous transperineal placement of radioactive gold seed for treatment of localized prostatic carcinoma. J Endourol. 1989;3(2):201-8.